Information on this website is provided for informational purposes only and is not a substitute for professional medical advice.
Elevated levels of lipoprotein(a), or Lp(a), significantly affect blood coagulation and are associated with an increased risk of blood clots.
High Lp(a) levels (typically greater than or equal to 50 mg/dL or greater than or equal to 25 nmol/L) act as a prothrombotic, or clotting-promoting, factor in several ways:
Inhibits Clot Breakdown (Antifibrinolytic): The structure of apolipoprotein(a) [apo(a)] is very similar to plasminogen, a protein that helps break down blood clots. Lp(a) competes with plasminogen, hindering the body’s ability to dissolve clots (fibrinolysis).
Increases Clot Formation: High Lp(a) promotes the activation and aggregation of platelets, which can lead to the formation of blood clots, especially in the arteries.
Induces Inflammation: Lp(a) carries oxidized phospholipids (OxPLs) to the vessel wall, which increases inflammation and can make atherosclerotic plaques more prone to rupture, triggering immediate clot formation.
Alters Clot Structure: Lp(a) is associated with the formation of denser, more rigid fibrin clots that are more resistant to being broken down.
Inhibits Natural Anticoagulants: Lp(a) binds to and inhibits tissue factor pathway inhibitor (TFPI), a natural anticoagulant in the body.
While high Lp(a) is a well-established independent risk factor for arterial diseases like heart attack, stroke, and peripheral artery disease due to these clotting-promoting effects, studies on whether it causes venous thromboembolism (blood clots in the veins) are less consistent, with some data suggesting it only impacts risk at extremely high levels.
Lp(a) is primarily genetically determined, meaning it is not generally lowered by diet or exercise.
In patients with high Lp(a), doctors may focus on aggressive management of other risk factors and, in some cases, consider low-dose aspirin to mitigate the increased clotting risk.